NASDAQ:OVID Ovid Therapeutics (OVID) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free OVID Stock Alerts $2.73 +0.01 (+0.37%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$2.69▼$2.7850-Day Range$2.72▼$4.0452-Week Range$2.22▼$4.14Volume272,979 shsAverage Volume159,045 shsMarket Capitalization$193.04 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ovid Therapeutics alerts: Email Address Ovid Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside248.0% Upside$9.50 Price TargetShort InterestBearish6.23% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.54Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.63) to ($0.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.67 out of 5 starsMedical Sector324th out of 947 stocksPharmaceutical Preparations Industry154th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingOvid Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Ovid Therapeutics has a forecasted upside of 248.0% from its current price of $2.73.Amount of Analyst CoverageOvid Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.23% of the float of Ovid Therapeutics has been sold short.Short Interest Ratio / Days to CoverOvid Therapeutics has a short interest ratio ("days to cover") of 22.9, which indicates bearish sentiment.Change versus previous monthShort interest in Ovid Therapeutics has recently increased by 1.39%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOvid Therapeutics does not currently pay a dividend.Dividend GrowthOvid Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOvid Therapeutics has received a 71.15% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for Epilepsy or seizures" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Ovid Therapeutics is -0.85. Previous Next 2.5 News and Social Media Coverage News SentimentOvid Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ovid Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for OVID on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ovid Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.60% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.64% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ovid Therapeutics are expected to grow in the coming year, from ($0.63) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ovid Therapeutics is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ovid Therapeutics is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOvid Therapeutics has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Ovid Therapeutics Stock (NASDAQ:OVID)Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Read More OVID Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OVID Stock News HeadlinesMarch 17, 2024 | insidermonkey.com5 Oversold Biotech Stocks To Buy Right NowMarch 13, 2024 | markets.businessinsider.comOvid Therapeutics: Strong Buy Rating on Robust Pipeline and Strategic PartnershipsMarch 18, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 13, 2024 | news.yahoo.comOvid gas station, state and local officials dealing with contaminated fuel problemMarch 13, 2024 | msn.comOvid gas station shut down after discovery of water inside pumpsMarch 11, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)March 9, 2024 | finance.yahoo.comOVID Oct 2024 7.500 callMarch 8, 2024 | benzinga.comRecap: Ovid Therapeutics Q4 EarningsMarch 18, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 8, 2024 | globenewswire.comOvid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | investing.comOvid Therapeutics Inc (OVID)February 28, 2024 | globenewswire.comOvid Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | news.yahoo.comOvid-Elsie girls win third straight conference titleFebruary 17, 2024 | finance.yahoo.comOVID Mar 2024 5.000 callFebruary 17, 2024 | finance.yahoo.comOVID Apr 2024 5.000 callFebruary 15, 2024 | msn.comTaysha transfers rights to 3 programs, extends cash runway into 2026February 6, 2024 | finance.yahoo.comOvid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 1, 2024 | msn.comCirculatory cholesterol levels are inversely linked to mortality of patients with sepsis and critical illnessJanuary 18, 2024 | finance.yahoo.comOwning 31% shares,hedge funds owners seem interested in Ovid Therapeutics Inc. (NASDAQ:OVID),January 3, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Ovid Therapeutics (OVID)January 2, 2024 | finance.yahoo.comEnavate Sciences Backs Graviton Bioscience in Financing Round to Advance Development of Selective ROCK2 InhibitorsDecember 22, 2023 | benzinga.comOvid Therapeutics Stock (NASDAQ:OVID), Analyst Ratings, Price Targets, PredictionsDecember 21, 2023 | benzinga.comOvid Therapeutics Stock (NASDAQ:OVID) Dividends: History, Yield and DatesDecember 21, 2023 | msn.comBTIG Initiates Coverage of Ovid Therapeutics (OVID) with Buy RecommendationDecember 19, 2023 | finance.yahoo.comS&W Seed Company Appoints Jeffrey Rona to Its Board of DirectorsDecember 1, 2023 | finance.yahoo.comOvid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)November 16, 2023 | morningstar.comOvid Therapeutics Inc OVIDSee More Headlines Receive OVID Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2023Today3/18/2024Next Earnings (Estimated)5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OVID CUSIPN/A CIK1636651 Webwww.ovidrx.com Phone(646) 661-7661FaxN/AEmployees39Year Founded2014Price Target and Rating Average Stock Price Target$9.50 High Stock Price Target$11.00 Low Stock Price Target$8.00 Potential Upside/Downside+248.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,340,000.00 Net Margins-13,351.53% Pretax Margin-13,351.79% Return on Equity-49.76% Return on Assets-38.16% Debt Debt-to-Equity Ratio0.17 Current Ratio9.55 Quick Ratio10.59 Sales & Book Value Annual Sales$390,000.00 Price / Sales494.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.88 per share Price / Book1.45Miscellaneous Outstanding Shares70,710,000Free Float61,801,000Market Cap$193.04 million OptionableOptionable Beta0.72 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Jeremy Max Levin Ba Zoology (Age 71)Dphil, Mb Bchir, President, CEO & Chairman Comp: $923.54kMr. Jeffrey A. Rona (Age 56)Principal Financial Officer, Principal Accounting Officer & Chief Business and Financial Officer Comp: $686.28kMr. Jason Tardio M.B.A. (Age 46)Chief Operating Officer Comp: $652.84kMs. Lora PikeSenior Director of Investor Relations & Public RelationsMr. Thomas Michael Perone J.D. (Age 58)M.B.A., General Counsel Comp: $632.11kMr. Simon D. Kelner (Age 50)Chief Human Resources Officer Dr. Dirk Haasner (Age 59)Senior Vice President of Global Manufacturing & CMC QA Comp: $416.95kDr. Todd F. Baumgartner M.D.M.P.H., Senior Vice President of Regulatory AffairsDr. Julia Tsai Ph.D. (Age 49)Senior Vice President of Clinical Development Ms. Meg AlexanderChief Strategy OfficerMore ExecutivesKey CompetitorsAlimera SciencesNASDAQ:ALIMSpruce BiosciencesNASDAQ:SPRBAbeona TherapeuticsNASDAQ:ABEOGeneration BioNASDAQ:GBIOVaccitechNASDAQ:VACCView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 23,360 shares on 3/11/2024Ownership: 4.230%Goldman Sachs Group Inc.Bought 5,039 shares on 3/1/2024Ownership: 0.087%Virtu Financial LLCBought 24,264 shares on 2/26/2024Ownership: 0.034%Vanguard Group Inc.Bought 23,360 shares on 2/15/2024Ownership: 4.230%Bridgeway Capital Management LLCSold 19,355 shares on 2/15/2024Ownership: 0.622%View All Institutional Transactions OVID Stock Analysis - Frequently Asked Questions Should I buy or sell Ovid Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OVID shares. View OVID analyst ratings or view top-rated stocks. What is Ovid Therapeutics' stock price target for 2024? 2 brokers have issued 12 month target prices for Ovid Therapeutics' stock. Their OVID share price targets range from $8.00 to $11.00. On average, they anticipate the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 248.0% from the stock's current price. View analysts price targets for OVID or view top-rated stocks among Wall Street analysts. How have OVID shares performed in 2024? Ovid Therapeutics' stock was trading at $3.22 at the start of the year. Since then, OVID shares have decreased by 15.2% and is now trading at $2.73. View the best growth stocks for 2024 here. When is Ovid Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our OVID earnings forecast. How were Ovid Therapeutics' earnings last quarter? Ovid Therapeutics Inc. (NASDAQ:OVID) posted its earnings results on Monday, March, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. The company had revenue of $0.05 million for the quarter. Ovid Therapeutics had a negative trailing twelve-month return on equity of 49.76% and a negative net margin of 13,351.53%. What other stocks do shareholders of Ovid Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Enphase Energy (ENPH), Gilead Sciences (GILD) and Novavax (NVAX). When did Ovid Therapeutics IPO? (OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers. Who are Ovid Therapeutics' major shareholders? Ovid Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rubric Capital Management LP (7.52%), Vanguard Group Inc. (4.23%), Vanguard Group Inc. (4.23%), Blue Owl Capital Holdings LP (1.22%), Northern Trust Corp (0.69%) and Bridgeway Capital Management LLC (0.62%). Insiders that own company stock include Amit Rakhit and Jason Tardio. View institutional ownership trends. How do I buy shares of Ovid Therapeutics? Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OVID) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetryDid you make $29,000 two days with AI options trades?Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.